RSS_IDENT_s_31305009_b_1_3_9
 3.7 Frequent RAS pathway mutations in t(17;19)‐ALL cell lines Association of gene mutation in the RAS pathway with poor therapeutic outcome in childhood ALL is controversial.32, 33, 34, 35 However, gene mutation in the RAS pathway is frequently observed in patients’ samples of t(17;19)‐ALL.17 Thus, we sequenced four RAS pathway genes (KRAS, NRAS, PTPN11, and NF1) in t(17;19)‐ALL and t(1;19)‐ALL cell lines using a next generation sequencer (Table 4, Figure 6A). Mutations in PTPN11, NRAS, KRAS, and NF1 genes were detectable in one, two, two, and none of the four t(17;19)‐ALL cell lines, respectively, and gene mutation in RAS pathway was detectable in all t(17;19)‐ALL cell lines. In contrast, mutations in PTPN11, NRAS, KRAS, and NF1 genes were detectable in none, three, four, and one of 16 t(1;19)‐ALL cell lines, respectively, and gene mutation in RAS pathway was detectable in seven out of 16 t(1;19)‐ALL cell lines. Incidence of RAS pathway mutation tended to be higher in t(17;19)‐ALL cell lines than in t(1;19)‐ALL cell lines (P = 0.094 in chi‐square test). Table 4 RAS pathway mutation Cell line Gene Allele frequency Type of mutation Codon AA t(17;19) HALO1 NRAS 0.831 HOM Ggt/Agt G12S PTPN11 0.39 HET Tca/Cca S502P YCUB2 NRAS 0.486 HET cAa/cTa Q61L Endokun KRAS 0.8 HOM ggc/gTGGgc G13VG UOCB1 KRAS 0.464 HET Ggt/Cgt G12R t(1;19) KOPN‐K KOPN34 NRAS 0.444 HET Ggt/Agt G12S NF1 0.432 HET Acc/Gcc T940A KOPN36 KOPN54 KOPN60 KOPN63 YAMN90R KRAS 0.444 HET gGt/gTt G12V YAMN92 NRAS 0.392 HET gGa/gTa G60V YCUB6 KRAS 0.518 HET gCc/gAc A18D YCUB8 Kasumi2 KRAS 0.465 HET Gta/Cta V14L NF1 0.505 HET gaG/gaT E1699D THP4 SCMCL1 697 NRAS 0.482 HET gGt/gAt G12D RCH KRAS 0.482 HET Gta/Ata V14I PreALP John Wiley & Sons, Ltd Figure 6 Significance of RAS pathway mutation. (A) Genetic landscape of RAS pathway in four t(17;19)‐ALL cell lines and 16 t(1;19)‐ALL cell lines. P value between incidence of mutation in t(17;19)‐ALL cell lines and that in t(1;19)‐ALL cell lines in chi‐square test is shown. (B) Sensitivity to Selumetinib. In left panel, IC50 of Selumetinib was compared between t(17;19)‐ALL cell lines and t(1;19)‐ALL cell lines. In right panel, IC50 of Selumetinib was compared between cell lines with KRAS mutation and those without it. Heptagrams and circles indicate cell lines with KRAS mutation and those without it, respectively. Red and light green symbols indicate t(17;19)‐ALL and t(1;19)‐ALL cell lines, respectively. (C) Multi‐agent resistance of t(1;19)‐ALL cell lines with RAS pathway mutation. Total score of sensitivities to three (Pred, VCR, and L‐Asp), four (Pred, VCR, L‐Asp, and DNR), and five (Pred, VCR, L‐Asp, DNR, and MAF) agents were compared among t(17;19)‐ ALL cell lines, t(1;19)‐ALL cell lines with RAS pathway mutation, and t(1;19)‐ALL cell lines without RAS pathway mutation. P‐values in Mann‐Whitney test are shown.
